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Aims Cardiac resynchronization therapy (CRT) may exert its beneficial haemodynamic effect by improving ventricular syn-
chrony and improving atrioventricular (AV) timing. The aim of this study was to establish the relative importance of the
mechanisms through which CRT improves cardiac function and explore the potential for additional improvements with
improved ventricular resynchronization.
Methods and
Results
We performed simulations using the CircAdapt haemodynamic model and performed haemodynamic measurements
while adjusting AV delay, at low and high heart rates, in 87 patients with CRT devices. We assessed QRS duration, pres-
ence of fusion, and haemodynamic response. The simulations suggest that intrinsic PR interval and the magnitude of
reduction in ventricular activation determine the relative importance of the mechanisms of benefit. For example, if
PR interval is 201 ms and LV activation time is reduced by 25 ms (typical for current CRT methods), then AV delay
optimization is responsible for 69% of overall improvement. Reducing LV activation time by an additional 25 ms pro-
duced an additional 2.6 mmHg increase in blood pressure (30% of effect size observed with current CRT). In the clinical
population, ventricular fusion significantly shortened QRS duration (D-27+23 ms, P, 0.001) and improved systolic
blood pressure (mean 2.5 mmHg increase). Ventricular fusion was present in 69% of patients, yet in 40% of patients
with fusion, shortening AV delay (to a delay where fusion was not present) produced the optimal haemodynamic
response.
Conclusions Improving LV preloading by shortening AV delay is an important mechanism through which cardiac function is improved
with CRT. There is substantial scope for further improvement if methods for delivering more efficient ventricular re-
synchronization can be developed.
Clinical Trial
Registration
Our clinical data were obtained from a subpopulation of the British Randomised Controlled Trial of AV and VV Op-
timisation (BRAVO), which is a registered clinical trial with unique identifier: NCT01258829, https://clinicaltrials.gov
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Resynchronization † Cardiac resynchronization therapy † CRT † AV delay † CRT mechanisms
* Corresponding author. Tel: +44 207 594 1795; fax: +44 207 594 1706. E-mail address: darrel@drfrancis.org
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Europace
doi:10.1093/europace/euw136
Introduction
Cardiac resynchronization therapy (CRT) is an established treat-
ment for patients with heart failure and left bundle branch block
(LBBB) or complete heart block (CHB). However, despite treat-
ment, morbidity and mortality remain high.1
The current assumption is that the predominant mechanism of
action of CRT is ventricular resynchronization. However, improving
LV filling (preload) by shortening effective atrioventricular (AV) de-
lay to a more optimal value is also a potential mechanism through
which CRT may improve function.2 – 5 Adjusting AV delay during
CRT has previously been shown to have a powerful effect on acute
haemodynamics.3,6 – 8 The relative importance of these two me-
chanisms has not been well characterized since differentiating the in-
dividual effect of each mechanism on measures of cardiac function is
challenging.
Currently, routine delivery of CRT is via the coronary sinus in
conjunction with endocardial right ventricular (RV) and right atrial
leads. While CRT delivered in this way to patients with LBBB is
proved beneficial, it does not appear to fully reverse the underlying
conduction impairment.9 Therefore, an opportunity exists to im-
prove the delivery of ventricular resynchronization therapy, and it
remains unclear how much extra improvement in cardiac function
could be expected with improved resynchronization.
In this study, we aimed to answer the following questions: First,
what is the contribution of shortening AV delay to the overall im-
provement in cardiac function obtained with CRT? Second, what
magnitude of additional improvement in cardiac function would
be expected if methods for improving the delivery of ventricular re-
synchronization could be achieved?
We address these mechanistic questions regarding the physiology
of the acute beneficial effects of CRT using both computer simulations
and clinical data. The computer simulations allowed us to address
questions which are difficult to answer using clinical data alone.
We then tested the hypotheses generated using the computer
model in patients using high-precision haemodynamic measurements.
This verification of the simulation data with clinical data is important.
Methods
Computer simulations
The CircAdapt computational model of the human heart and circula-
tion10,11 was used to quantify the magnitude of improvement in cardiac
function available through AV delay optimization only (i.e. without
changing ventricular activation pattern) and in combination with differ-
ent degrees of left ventricular (LV) resynchronization.
First, a failing heart with LBBB was simulated (Figure 1A), intrinsic AV
delay was prolonged to 220 ms, and heart rate was set to 80 bpm.
Haemodynamic measurements for all other simulations were compared
with this reference simulation. Next, we simulated the degree of ven-
tricular resynchronization obtained with current methods for delivering
CRT (Figure 1B), resulting in a 25 ms shortening of total LV activation
time. Finally, two further simulations of more successful ventricular re-
synchronization were performed, i.e. additional 25 and 50 ms reduc-
tions in LV activation time (Figure 1C and D).
For all four LV activation patterns, we progressively shortened AV de-
lay from 220 to 20 ms (decrements of 10 ms) and plotted LV stroke
volume (SV) and aortic systolic blood pressure (SBP) as functions of
AV delay.
The CircAdapt model describes the physiological interactions
between its modules representing myocardial walls, cardiac valves,
large blood vessels, peripheral resistances, and the pericardium.10,12
Simulations of mechanical and haemodynamic interventricular(VV)
and AV interactions under normal and pathophysiological circumstances
have been validated in previous studies.10,13 We describe this model
further in the supplemental data file (Supplementary material online,
Appendix S1).
Study population
We recruited 87 consecutive patients with CRT devices, sinus rhythm,
and LBBB or CHB, and a power calculation is provided online in Supple-
mentary material online, Appendix S2. We adjusted AV delay at low and
high heart rates.
This was a sub-study of the British Randomised Controlled Trial of AV
and VV Optimisation (BRAVO, NCT0125882914). The BRAVO study
was designed to compare echocardiography-guided optimization with
haemodynamic optimization of AV and VV delays. All patients with a
clinically indicated but previously implanted CRT device (EF, 35% at
the time of implant) were included regardless of current LV function
or the presence or absence of clinical response.15
All patients gave written informed consent for the study, which was
approved by the local Research Ethics Committee.
For this sub-study, only patients with underlying LBBB QRS morph-
ology or CHB (and therefore 100% RV pacing) were included. Left bun-
dle branch block was defined as QRS duration above 120 ms and typical
12-lead electrocardiography morphology.16
Haemodynamic measurements
Blood pressure (BP) was measured using a Finometer device (Finapres
Medical System, The Netherlands) yielding a continuous arterial pres-
sure waveform.
In order to obtain a reliable assessment, we used the following
protocol. We compared each tested AV delay to a reference AV de-
lay of 120 ms and calculated the relative change in SBP. This was cal-
culated as the difference between the mean of 8 beats immediately
before and after the transition to the tested AV delay from the refer-
ence AV delay. We repeated this measurement a minimum of six
times for each tested AV delay and used this to calculate the mean
relative change in SBP for each tested delay.2 – 4 Tested AV delays
What’s new?
† It has been assumed that ventricular resynchronization is the
main mechanism through which cardiac resynchronization
therapy improves cardiac function.
† We found that improving LV preloading by shortening AV de-
lay plays a key role in the way CRT improves cardiac function.
This information may be useful when designing methods to
improve patient selection for CRT implantation.
† Current methods for delivering CRT do not fully reverse the
impairment in ventricular activation, which occurs with left
bundle branch block. The potential for extra improvement
in cardiac function, with better ventricular resynchronization,
has not previously been well characterized.
† We found that, encouragingly, there appears to be substantial
scope for obtaining additional improvements in cardiac func-
tion if novel forms of CRT that provide more efficient ven-
tricular resynchronization can be developed.
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were 40, 80, 140, 160, 200, 240, and 280 ms or up to an AV delay
where ventricular pacing was withheld by the device. When possible,
AAI mode pacing was also compared with the reference. The pro-
grammed AV delay yielding the greatest mean increase in BP was con-
sidered the optimum.
The protocol was carried out at two heart rates during atrial pacing:
low heart rate (5 bpm above resting heart rate) and high heart rate
(mean 103+ 6 bpm). VV delay was kept constant throughout the
measurements, and it was programmed to 0 ms or as close to this as
the device would allow.
Assessment of conduction pattern and atrioventricular
node decrementation
The ventricular activation pattern was assessed using the morphology of
the surface electrocardiogram (ECG), which was collected at each pro-
grammed AV delay at each heart rate. We classified ventricular
activation as follows:
† Pure intrinsic conduction: Ventricular activation results from ventricular
activation only. This was assessed during AAI pacing mode.
† CRT pacing with complete ventricular capture: Ventricular activation oc-
curs only as a result of the biventricular ventricular pacing stimuli.
This was assessed while pacing with an AV delay of 40 ms.
† Ventricular fusion: Ventricular activation results from a combination of
CRT pacing and intrinsic conduction. QRS morphology differs from
that obtained during CRT pacing with complete ventricular capture
and pure intrinsic conduction.
We calculated QRS duration using measurements from three separate
QRS complexes obtained at each tested AV delay. Measurements were
made using digitally stored electrograms with screen callipers at a paper
speed of 100 ms. We measured from the rapid deflection of the QRS in
order to avoid including the isoelectric period following the pacing spike
in the QRS measurement.
AV node decrementation was considered to be present if ventricular
fusion occurred at a longer programmed AV delay at high heart rate
compared with low heart rate.
Patient categorization
We divided our study population according to pre-specified criteria
based on the presence or absence of ventricular fusion and the conduc-
tion pattern offering the best haemodynamic response.
We subdivided patients who showed fused conduction according to
whether the highest haemodynamic response occurred with or without
fusion at low heart rate. We subdivided the group where the highest
haemodynamic response occurred with fusion according to whether
decrementation of intrinsic AV node conduction was present or absent.
Therefore, the following four subgroups were obtained:
(1) ‘No fusion’, CHB or very long intrinsic PR interval. Therefore, opti-
mal AV delay occurred with biventricular pacing (BVP) at both rates.
This group served as the control to assess the effect of increasing
atrial pacing on optimal AV delay timing when ventricular fusion is
not present.
(2) ‘Optimum, fusion’, the AV delay with the highest haemodynamic re-
sponse occurred at an AV delay without fusion at the low heart rate.
(3) ‘Fused optimum, without AV node decrementation’, the highest
haemodynamic response occurred with fusion at low heart rate,
and increasing heart rate did not delay onset of fusion.
(4) ‘Fused optimum with decrementation’, the highest haemodynamic
response occurred with fusion at low heart rate and increasing
heart rate delayed the onset of fusion (which occurred at a longer
AV delay compared with the low heart rate).
Statistical analysis
Data are presented as mean+ standard deviation (SD) or mean
difference+ SD of difference. Data were examined for normality prior
to further statistical analysis. Statistical comparisons of continuous data
were made using repeated measures one-way analysis of variance
(ANOVA) for within- or between-individual comparisons of more
than two groups as appropriate. Between-group testing was performed
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Figure 1 Simulated ventricular activation patterns. Four different
LV activation states were simulated: (A) typical LBBB; (B) LV activa-
tion time of 110 ms (CRT-110), which represents the typical elec-
trical resynchronization obtained with current CRT; and (C and
D) additional 25 and 50 ms reduction in ventricular activation
time, over and above that obtained with current CRT. This repre-
sents LV activation times of 85 ms (CRT-85) and 60 ms (CRT-60),
respectively. Red stars indicate RV and LV lead positions.
Potential for improved delivery of pacing therapy Page 3 of 9
if ANOVA was significant, paired t-tests for within-individual compari-
sons, and unpaired t-test for between-group comparisons. Comparisons
of categorical data were made using a x2 test.
Results
Computer simulations
Relative contribution of atrioventricular delay
optimization and ventricular resynchronization
We adjusted AV delay in the CircAdapt model without changing the
baseline LBBB-related dyssynchrony of ventricular activation. The
effect on SV and BP depended on the starting AV delay (Figure 2).
For example, using a PR interval of 201 ms (the average in our study
population), AV delay optimization generated a 6 mmHg increase in
SBP without changing the ventricular activation pattern.
During simulated CRT pacing (a 25 ms reduction in LV activation
time compared with LBBB), we observed a further 2.7 mmHg in-
crease in SBP on top of that obtained with AV delay optimization
only. Therefore, for this example simulation with an intrinsic PR
interval of 201 ms, AV delay optimization accounted for 69% of
the overall available improvement in cardiac function (6/(6 +
2.7) × 100).
Potential for further improvements in cardiac function
with improved delivery of ventricular resynchronization
A 25 ms reduction in LV activation time (Figure 2: CRT-85) relative
to current standard CRT pacing (Figure 2: CRT-110) resulted in an
additional 2.6 mmHg increase in SBP, while an additional 50 ms re-
duction in LV activation time (Figure 2: CRT-60) produced a
4.6 mmHg increase in SBP. With an intrinsic PR interval of
201 ms, these increases in SBP represent 30% ((2.6/8.7) × 100)
and 53% ((4.6/8.7) × 100), respectively, of the total improvement
observed with CRT using current methods for delivery and optimal
AV delay.
Clinical data
The characteristics of the 87 patients, recruited from 18 different
centres within the UK, are shown in Table 1.
Effect of heart rate on atrioventricular delay determined as
optimal
Patients were categorized according to the pre-specified criteria de-
scribed above (Figure 3). Mean difference between the AV delay op-
tima determined at the low- and the high-paced heart rate was
calculated for each group and compared between four groups
(P ¼ 0.09). Post hoc analysis revealed a significantly greater differ-
ence in Group 4 (D-30+ 45 ms) vs. all other groups (D-9+
39 ms, P ¼ 0.05). Diagrammatic representation of the difference be-
tween low and high heart rate optima is presented in the supple-
mental data (Supplementary material online, Figure S1).
The difference in AV delay determined as optimal between low
and high heart rates is as follows for the four groups of patients.
Group 1. ‘No fusion’, comprising 27 patients with CHB (n ¼ 18) or
very long intrinsic PR interval (n ¼ 9). No significant difference
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Figure 2 Simulation-based assessment of the relative importance of AV delay optimization and left ventricular activation time (LVAT) with cur-
rent CRT methods and predicted impact of additional improvements in LV resynchronization. The left plot shows the relationship between AV
delay and SV, and the right plot shows the relationship between AV delay and SBP. Four different ventricular activation states are displayed. Typical
LBBB (LV activation time 135 ms). The typical electrical resynchronization obtained with current CRT [LV activation time of 110 ms (CRT-110)].
Additional 25 and 50 ms reductions in ventricular activation time, over and above that obtained with current CRT [LV activation times of 85 ms
(CRT-85) and 60 ms (CRT-60)]. The Turquoise vertical arrow shows the improvement gained from optimizing AV timing relative to a baseline AV
delay of 200 ms. Improvements gained from each additional reduction in LVAT are indicated by the red vertical arrows.
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was found between the AV delay determined as optimal at the
low and the high rates (D-9+48 ms, P ¼ 0.32).
Group 2. ‘Optimum , fusion’, comprising 24 patients in whom fu-
sion only occurred at AV delays longer than the haemodynamic
optimum. Despite the option to improve ventricular synchrony
(with ventricular fusion), the AV delay producing the highest
haemodynamic response occurred with BVP with complete ven-
tricular capture, and there was no significant change in AV delay
identified as optimal at the high heart rate (D-4+ 28 ms, P ¼
0.46). This group comprises 40% of the population where fusion
was available.
The AV delay at which fusion first occurred was significantly longer
in Group 2, mean 231+45 ms compared with Group 3 (mean
200+33 ms) and Group 4 (203+46 ms), P ¼ 0.02.
Group 3. ‘Fused optimum, without AV node decrementation’, com-
prising 10 patients in whom the onset of fusion was not delayed
by pacing at the higher heart rate. The optimal AV delay did not
significantly differ between low and higher rate pacing (D-20+
34 ms, P ¼ 0.096).
Group 4. ‘Fused optimum with decrementation’, comprising 26 pa-
tients in whom the low-rate optimum occurred during fusion and
the higher heart rate delayed fusion by decrementing AV conduc-
tion. There was a significant shortening of the AV delay identified
as optimal at the high heart rate (D-30+ 45 ms, P ¼ 0.002).
Further analysis of this group showed that in the majority of
patients (77%), the optimal AV delay switched from occurring
in the fusion zone at low rate to CRT pacing with complete ven-
tricular capture at the high rate, and this was significant by x2 test
(P ¼ 0.009).
Ventricular resynchronization with current methods for
delivering cardiac resynchronization therapy
We quantified electrical ventricular resynchronization, in all patients
who demonstrated fusion (regardless of group), by comparing QRS
duration in three states (mean QRS+ SD): (a) intrinsic conduction
(176+ 25 ms), (b) CRT pacing with complete ventricular capture
(164+ 29 ms), and (c) BVP with fusion (137+ 26 ms, P, 0.001).
These values were compared with previously published mean
QRS duration from healthy subjects17 (Figure 4). There was a signifi-
cant difference in QRS duration between the three conduction
states (three-way ANOVA, P, 0.001), and post hoc analysis showed
that QRS duration was significantly narrower during fusion com-
pared with CRT pacing with complete ventricular capture
(D-27+ 23 ms, P, 0.001) and significantly narrower with BVP
than intrinsic conduction (D-12+35 ms, P ¼ 0.009). QRS duration
and intrinsic PR interval are provided for each group in the supple-
mental data (see Supplementary material online, Table S1).
Example haemodynamic data from each group are shown in
Figure 5.
Assessment of haemodynamic impact of ventricular fusion
Group 4 allowed us to examine the association between fusion and
acute haemodynamics since at low heart rate, the highest haemo-
dynamic response occurred with fusion, but at high heart rate, the
onset of fusion was delayed. Loss of fusion was associated with a
mean decline in SBP, this is to say; mean relative SBP at the low heart
rate optimal AV delay (fusion) minus the mean relative SBP at the
same AV delay at high heart rate (without fusion) is D-2.5 mmHg,
Table 1 Patient demographics
Demographic % (n ¼ 87)
Gender
Male 78
Age (years+ SD) 67.3+11.7
NYHA Functional Class
II 93
III 7
Months post-implant+ SD 83+143
Medication
ACE/ARB inhibitors 87
Beta-Blockers 92
Digoxin 14
Furosemide 53
Spironolactone 41
Ischaemic aetiology 60
Intrinsic ECG measurements (n ¼ 69)
PR interval (ms) 203+45
QRS duration (ms) 175+25
Echocardiographic measurements
LA dimension (cm) 4.5+0.72
LVEDD (cm) 5.81+1.14
LVESD (cm) 4.92+1.10
Ejection fraction (%) 40.5+10
Data are means+ SD or percentage of participants (%).
LA, left atrium; LVEDD, left ventricular end diastolic dimension; LVESD, left
ventricular end systolic dimension.
Patients enrolled for AVD optimization
at low and high heart rates
n = 87
>90% BVP paced, sinus rhythm
No fusion
n = 27
CHB or very long
intrinsic PR interval
Optimum < fusion
n = 24
at low rate, optimum occurs
at a shorter AVD than fusion
Fused optimum and AV node
decrementation present
n = 26
Fused optimum and AV node
decrementation absent
n = 10
Figure 3 Categorization of patients. Patients were grouped ac-
cording to their optimal AV delay determined by haemodynamic
optimization at low and high heart rates and by the presence or
absence of AV node decrementation. BVP and CHB.
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SDD 4.03, P ¼ 0.004. We can say that, at a constant AV delay, fusion
improved SBP by 2.5 mmHg and, in this group of patients, the
haemodynamic improvement corresponded to a 22+ 25 ms
reduction in QRS duration.
Discussion
Our findings from computer simulations and clinical data provide
complementary evidence to suggest that, first, improving LV pre-
loading by AV delay shortening is a fundamental mechanism through
which CRT delivers its beneficial effect. Second, delivery of more ef-
ficient ventricular resynchronization has the potential to produce
important additional improvements in cardiac function.
The simulations suggest that a 50 ms reduction in LV activation
time would deliver an effect size equivalent to 53% of the total im-
provement observed with current methods for delivering CRT. The
clinical data confirm that CRT currently does not produce complete
electrical ventricular resynchronization and supports evidence from
the simulations by showing that further reductions in QRS duration,
produced by ventricular fusion, positively influence acute haemo-
dynamic function.
Improving atrioventricular timing is a
critical component of the mechanism
through which CRT delivers its beneficial
effect
The results of the computational simulations suggest that AV delay
optimization is fundamental to the mechanism through which CRT
delivers its beneficial effect. The computational model of the human
heart and circulation allowed us to independently quantify the ef-
fects of AV delay optimization and ventricular resynchronization.
Both AV shortening and ventricular resynchronization had clear
beneficial effects on acute haemodynamic function. The simulations
demonstrated that the relative importance of the mechanisms of
benefit is dependent on the baseline PR interval and the magnitude
of the reduction in LV activation time with CRT. While these factors
are patient specific, the results of the simulations suggest that im-
proving LV preload through AV shortening is a key mechanism
through which CRT currently improves cardiac function, when it
is delivered to patients in sinus rhythm. Other factors such as intera-
trial conduction time may also affect the balance between the two
mechanisms of benefit.
The findings from the clinical data support the findings from the
computer simulations. In 40% of patients with ventricular fusion, and
therefore with the potential to obtain improved ventricular resyn-
chronization compared with complete ventricular capture, the high-
est haemodynamic response occurred at an AV delay with complete
ventricular capture. If delivering improved ventricular electrical re-
synchronization was the sole mechanism through which CRT deliv-
ered its beneficial effect, then one would expect the optimal AV
delay to always occur with fusion since this appears to deliver the
most efficient ventricular activation. In this group of patients (Group
2), it appears the beneficial effects of fusion with respect to electrical
ventricular resynchronization were outweighed by the negative im-
pact on LV preload resulting from a suboptimal AV delay. In this
group, fusion occurred at longer AV delays compared with the
groups (3 and 4) where fusion resulted in the highest haemodynamic
response (Supplementary material online, Table S1). Furthermore,
in the group where there was a delayed onset of fusion with higher
rate pacing (Group 4), the optimal AV delay shortened, rather than
lengthened as would be expected if ventricular resynchronization
was the only mechanism through which CRT delivers its beneficial
effect.
The finding that shortening AV delay is an important mechanism
through which CRT delivers its beneficial effect is supported by the
findings of a sub-analysis of the COMPANION study, where pa-
tients with a longer PR interval were shown to obtain a greater rela-
tive risk reduction.18
Previous trials, reporting clinical outcomes, have suggested that
AV optimization using electrical algorithms or echocardiographic
methods, do not influence CRT outcome.19 In these studies, AV de-
lay was shortened relative to sinus rhythm, in all patients including
those in the control group where a nominal AV delay was pro-
grammed. Therefore, these studies were not designed to assess
whether improving AV timing compared with sinus rhythm contri-
butes to the overall mechanism through which CRT produces its
beneficial effects.
Potential for additional improvements
in cardiac function with improved
ventricular resynchronization
CRT pacing with complete ventricular capture produced only mo-
dest reductions in QRS duration (Figure 4) implying that CRT has
only modest effects on ventricular electrical synchrony. Our findings
are consistent with studies that have assessed the effect of CRT
using ventricular activation mapping20,21 and large clinical trials re-
porting changes in QRS duration.22
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Figure 4 Untapped potential for ventricular resynchronization.
QRS duration is shown during intrinsic conduction (no CRT), with
CRT, and with CRT pacing allowing fusion of paced and intrinsic
conduction, and previously published data for QRS duration
from healthy subjects are shown for normal conduction.17
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The computer simulation data suggested that improvements in
cardiac function could be obtained if methods for delivering more
efficient ventricular resynchronization can be developed. Encour-
agingly, the findings from the simulations were supported by the
clinical data. Ventricular fusion appeared to deliver more efficient
ventricular activation; the QRS duration during fusion was signifi-
cantly shorter. We observed a 2.5 mmHg improvement in BP in
the presence of fusion compared with when fusion was not present,
at the same AV delay in the same patient. The corresponding reduc-
tion in QRS duration with this BP improvement was 22 ms. This
change in SBP was similar to the magnitude of change observed
with the simulations (2.7 mmHg for a 25 ms reduction in LV
activation time). Our finding of a reduction in QRS duration and im-
provement in acute haemodynamic function during fusion is consist-
ent with the findings of other investigators.23
However, even with fusion, ventricular electrical activation ap-
pears to be far from normal, with mean QRS duration considerably
longer than reports from healthy subjects (93+ 10 ms)17 (Figure 4)
suggesting scope for even greater improvements in cardiac function.
Clinical application of these findings
These findings are relevant to clinical practice for the following rea-
sons. Firstly, understanding the true ratio of the mechanisms of CRT
benefit may allow better characterization of the patient population
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Figure 5 Example haemodynamic optimization data from an individual patient in each group. Low (Turquoise) and high (red) heart rates for
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most likely to obtain benefit. Given that improving AV timing ap-
pears to be the dominant mechanism of benefit under most circum-
stances, better characterizing AV mistiming in addition to electrical
measures of ventricular dyssynchrony may improve patient selec-
tion. Secondly, the finding that there is considerable scope for deli-
vering improved ventricular resynchronization should stimulate the
scientific community to develop methods for improving the way
therapy is delivered.
Suitability of systolic blood pressure as marker of acute
cardiac function
We chose SBP as our marker of acute cardiac function for the fol-
lowing reasons:
† It is an extra cardiac measure and therefore represents the net
effect on cardiac function occurring as a result of the changes
in pacemaker settings.
† Multiple repeated measurements can be made in order to minim-
ize the effect of noise, which is present in all measures of cardiac
function. This allows reproducible results to be obtained.24
† Changes in BP reflect changes in other markers of cardiac func-
tion such as LV dp/dtmax and aortic flow.
25
In patients with heart failure, it is known that higher BP is associated
with better outcomes.26 Cardiac resynchronization therapy when
delivered to patients with LBBB is associated with acute improve-
ments in SBP.7 Sustained improvements in SBP were observed in
the randomized studies assessing longer-term outcomes with
CRT. For example in the Care-HF study, a 6.3 mmHg increase in
SBP was observed in the treatment arm 18 months follow-up.1
Limitations
This study did not assess clinical endpoints; it was designed to make
high-resolution comparisons between AV delay settings at two dif-
ferent paced heart rates in a manner that explored physiological me-
chanisms. Testing for an effect on clinical endpoints would require a
large randomized trial. Such a trial would be justified once candidate
methods of delivering better ventricular resynchronization have
been tested in studies that could be acute but must be bias
resistant.27
We used the well-established CircAdapt10,11 computational sys-
tem to address mechanistic questions that could not be directly ad-
dressed in humans. All such computations should be interpreted
with caution. However, for the questions which could be answered
clinically as well as computationally, the results from both ap-
proaches were concordant.
The patients recruited into the clinical part of the study all had
their CRT devices implanted prior to inclusion in the study. It is likely
that they will have already experienced remodelling following device
implantation; it is possible that this could have affected the results of
the study.
It is possible that LV lead position could influence the optimal AV
delay, and we did not aim to address this question in the present
study. Lead positions were kept constant in individual patients
throughout the study.
The AV delay providing the highest haemodynamic response is
patient specific. It is likely that this is dependent on many factors
which we did not aim to investigate in the present study. In order
to keep these factors constant, we calculated relative change in op-
timal AV delay in individual patients, thereby keeping lead position
and cardiac substrate constant when investigating the effect of chan-
ging heart rate and the presence or absence of fusion.
Conclusions
Current methods for delivering CRT result in modest reductions in
QRS duration, suggesting incomplete reversal of electrical dyssyn-
chrony. With current methods for delivering CRT, improving LV
preloading by AV delay shortening appears to be an important
mechanism through which therapy improves cardiac function. Our
computational calculations and clinical data suggest substantial fur-
ther scope for delivering improvements in cardiac function if novel
forms of CRT could be developed to provide more efficient ven-
tricular resynchronization.
Supplementary material
Supplementary material is available at Europace online.
Acknowledgements
We thank the members of the BRAVO investigator group without
which this study would not be possible: Nishi Chaturvedi, Wyn Da-
vies, Boon Lim, David Lefroy, Nicholas S. Peters, Emma Coady,
Katherine March, Suzanne Williams, Karikaran Manoharan, Nadia
Do Couto Francisco, Vasco Miranda Carvalho, Andreas Kyriacou,
Amelia Rudd, Nadiya Sivaswamy, Satnam Singh, Martin Thomas,
Jon Swinburn, Paul Foley, Tim Betts, David Webster, Dominic Ro-
gers, Tom Wong, Rakesh Sharma, Susan Ellery, Zaheer Yousef,
Lisa Anderson, Mohamed Al-Obaidi, Nicky Margerison, Stephanie
Barrett, Paul Kalra, Raj Khiani, and Mark Dayer. The authors are
grateful for the infrastructural support from the National Institute
for Health Research (NIHR) Biomedical Research Centre based at
Imperial College Healthcare NHS Trust and Imperial College Lon-
don. The authors are grateful for infrastructural support from the
Biomedical Research Centre based at Imperial College Healthcare
NHS Trust and Imperial College London.
Funding
This work was supported by the UK’s cardiovascular charity, the British
Heart Foundation (BHF) (SP/10/002/28189) and the National Institute
for Health Research. Z.W. (FS/13/44/30291), D.F. (FS/10/038), and
A.S. (FS/11/92/29122) receive funding from the BHF. J.L. receives fund-
ing from the Dr E. Dekker program of the Dutch Heart Foundation
(2012T010). Funding to pay the Open Access publication charges for
this article was provided by British Heart Foundation.
Conflict of interest: D.P.F. and Z.I.W. are named as inventors on a pa-
tent filed by Imperial College London on methods for haemodynamic
optimization of CRT pacemakers that reduce uncertainty.
References
1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al.
The effect of cardiac resynchronization on morbidity and mortality in heart failure.
N Engl J Med 2005;352:1539–49.
2. Whinnett ZI, Francis DP, Denis A, Willson K, Pascale P, van Geldorp I et al. Com-
parison of different invasive hemodynamic methods for AV delay optimization in
S. Jones et al.Page 8 of 9
patients with cardiac resynchronization therapy: implications for clinical trial design
and clinical practice. Int J Cardiol 2013;168:2228–37.
3. Whinnett ZI, Davies JE, Willson K, Chow AW, Foale RA, Davies DW et al. Deter-
mination of optimal atrioventricular delay for cardiac resynchronization therapy
using acute non-invasive blood pressure. Europace 2006;8:358–66.
4. Whinnett ZI, Briscoe C, Davies JE, Willson K, Manisty CH, Davies DW et al. The
atrioventricular delay of cardiac resynchronization can be optimized hemodynam-
ically during exercise and predicted from resting measurements. Heart Rhythm
2008;5:378–86.
5. Auricchio A, Salo RW. Acute hemodynamic improvement by pacing in patients
with severe congestive heart failure. Pacing Clin Electrophysiol 1997;20:313–24.
6. Whinnett ZI, Davies JE, Willson K, Manisty CH, Chow AW, Foale RA et al. Haemo-
dynamic effects of changes in atrioventricular and interventricular delay in cardiac
resynchronisation therapy show a consistent pattern: analysis of shape, magnitude
and relative importance of atrioventricular and interventricular delay. Heart 2006;
92:1628–34.
7. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P et al. Effect of pacing
chamber and atrioventricular delay on acute systolic function of paced patients
with congestive heart failure. The Pacing Therapies for Congestive Heart Failure
Study Group. The Guidant Congestive Heart Failure Research Group. Circulation
1999;99:2993–3001.
8. Bogaard MD, Meine M, Tuinenburg AE, Maskara B, Loh P, Doevendans PA. Cardiac
resynchronization therapy beyond nominal settings: who needs individual pro-
gramming of the atrioventricular and interventricular delay? Europace 2012;14:
1746–53.
9. Ploux S, Eschalier R, Whinnett ZI, Lumens J, Derval N, Sacher F et al. Electrical dys-
synchrony induced by biventricular pacing: implications for patient selection and
therapy improvement. Heart Rhythm 2015;12:782–91.
10. Lumens J, Delhaas T, Kirn B, Arts T. Three-wall segment (TriSeg) model describing
mechanics and hemodynamics of ventricular interaction. Ann Biomed Eng 2009;37:
2234–55.
11. Lumens J, Leenders GE, Cramer MJ, De Boeck BW, Doevendans PA, Prinzen FW
et al. Mechanistic evaluation of echocardiographic dyssynchrony indices: patient
data combined with multiscale computer simulations. Circ Cardiovasc Imaging
2012;5:491–9.
12. Arts T, Delhaas T, Bovendeerd P, Verbeek X, Prinzen FW. Adaptation to mechan-
ical load determines shape and properties of heart and circulation: the CircAdapt
model. Am J Physiol Heart Circ Physiol 2005;288:H1943–54.
13. Lumens J, Blanchard DG, Arts T, Mahmud E, Delhaas T. Left ventricular underfilling
and not septal bulging dominates abnormal left ventricular filling hemodynamics in
chronic thromboembolic pulmonary hypertension. Am J Physiol Heart Circ Physiol
2010;299:H1083–91.
14. ClinicalTrials.gov. ClinicalTrials.gov, U.S. National Institutes of Health: National Li-
brary of Medicine, 2014.
15. Nijjer SS, Sohaib SM, Whinnett ZI, Lefroy DC. Management of supraventricular ta-
chycardias. Br J Hosp Med 2014;75:C26–8.
16. Hampton JR. The ECG Made Easy. Edinburgh, New York: Churchill Livingstone
1992: vi, p106.
17. Macfarlane PW, McLaughlin SC, Devine B, Yang TF. Effects of age, sex, and race on
ECG interval measurements. J Electrocardiol 1994;27:14–9.
18. Olshansky B, Day JD, Sullivan RM, Yong P, Galle E, Steinberg JS. Does cardiac re-
synchronization therapy provide unrecognized benefit in patients with prolonged
PR intervals? The impact of restoring atrioventricular synchrony: an analysis from
the COMPANION Trial. Heart Rhythm 2012;9:34–9.
19. Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S, Waggoner AD
et al. Primary results from the SmartDelay determined AV optimization: a compari-
son to other AV delay methods used in cardiac resynchronization therapy
(SMART-AV) trial: a randomized trial comparing empirical, echocardiography-
guided, and algorithmic atrioventricular delay programming in cardiac resynchroni-
zation therapy. Circulation 2010;122:2660–8.
20. Ginks MR, Shetty AK, Lambiase PD, Duckett SG, Bostock J, Peacock JL et al. Ben-
efits of endocardial and multisite pacing are dependent on the type of left ventricu-
lar electric activation pattern and presence of ischemic heart disease insights from
electroanatomic mapping. Circ-Arrhythmia Elec 2012;5:889–97.
21. Ploux S, Eschalier R, Whinnett ZI, Lumens J, Derval N, Sacher F et al. Electrical dys-
synchrony induced by biventricular pacing: implications for patient selection and
therapy improvement. Heart Rhythm 2014;12:782–91.
22. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E et al. Cardiac
resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–53.
23. Arbelo E, Tolosana JM, Trucco E, Penela D, Borras R, Doltra A et al.
Fusion-optimized intervals (FOI): a new method to achieve the narrowest QRS
for optimization of the AV and VV intervals in patients undergoing cardiac resyn-
chronization therapy. J Cardiovasc Electrophysiol 2014;25:283–92.
24. Whinnett ZI, Davies JE, Nott G, Willson K, Manisty CH, Peters NS et al. Efficiency,
reproducibility and agreement of five different hemodynamic measures for opti-
mization of cardiac resynchronization therapy. Int J Cardiol 2008;129:216–26.
25. Manisty CH, Al-Hussaini A, Unsworth B, Baruah R, Pabari PA, Mayet J et al. The
acute effects of changes to AV delay on BP and stroke volume: potential implica-
tions for design of pacemaker optimization protocols. Circ Arrhythm Electrophysiol
2012;5:122–30.
26. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH et al.
Quantifying the paradoxical effect of higher systolic blood pressure on mortality
in chronic heart failure. Heart 2009;95:56–62.
27. Sohaib SM, Whinnett ZI, Ellenbogen KA, Stellbrink C, Quinn TA, Bogaard MD et al.
Cardiac resynchronisation therapy optimisation strategies: systematic classification,
detailed analysis, minimum standards and a roadmap for development and testing.
Int J Cardiol 2013;170:118–31.
Potential for improved delivery of pacing therapy Page 9 of 9
